In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy for 2025. Both conservative and risk-tolerant investors ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA.

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

In the new filing, Lilly says it wants to wade into the legal proceedings to “protect its interests and help bring this suit to a swift end.” The company’s lawyers further contend that OFA ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Senior equity analysts at StockNews.com upgraded Eli Lilly (LLY, Financial) stock from 'hold' to 'buy' as its stock has shifted positively. Analysts say the upgrade is a sign of increased ...

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. ‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could ...

Eli Lilly LLY has outperformed the market over the past 15 years by 11.32% on an annualized basis producing an average annual return of 22.84%. Currently, Eli Lilly has a market capitalization of ...